Crossmark Global Holdings, Inc. Ascendis Pharma A/S Transaction History
Crossmark Global Holdings, Inc.
- $5.61 Billion
- Q3 2024
A detailed history of Crossmark Global Holdings, Inc. transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Crossmark Global Holdings, Inc. holds 8,120 shares of ASND stock, worth $1.1 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
8,120Holding current value
$1.1 Million% of portfolio
0.02%Shares
1 transactions
Others Institutions Holding ASND
# of Institutions
244Shares Held
58.8MCall Options Held
250KPut Options Held
377K-
Ra Capital Management, L.P. Boston, MA9.71MShares$1.32 Billion20.22% of portfolio
-
Westfield Capital Management CO LP Boston, MA5.13MShares$697 Million3.62% of portfolio
-
Avoro Capital Advisors LLC New York, NY4.99MShares$677 Million11.21% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI4.41MShares$599 Million1.03% of portfolio
-
Janus Henderson Group PLC London, X04.19MShares$568 Million0.33% of portfolio
About Ascendis Pharma A/S
- Ticker ASND
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,810,200
- Market Cap $7.57B
- Description
- Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...